Alpha Nuclide
Latest round
- Series A
Last raised
- Feb 2026
Total raised
- Undisclosed
Investors
- 4
About Alpha Nuclide
, trading as Alpha Nuclide, is a drug developer dedicated to nuclide drug research. It has a R&D center in Hangzhou. The co-founder and CEO of the company, Yutian Feng, graduated from Duke University. The co-founder and chief adviser, Michael Zalutsky, is a professor at Duke University Medical Center and the founder of Cereius Inc. The core technical team comes from universities and research institutions such as the University of Pennsylvania and Brookhaven National Laboratory. The company's research areas include radionuclide drugs, nuclide production, alpha & beta nuclide comparison, and alpha nuclide comparison. It provides scientific research services and nucleide drug R&D contract outsourcing services to pharmaceutical companies, hospitals and colleges. The product pipelines cover liver cancer, lung cancer, breast cancer, and other tumor diseases. Asta Thera also supplies germanium-68, germanium-gallium generators, iodine-123, copper-64, thallium-201, and other new medical nuclides. The company generates revenue by providing scientific research services and nucleus drug research and development contract outsourcing services, as well as conducting nucleide drug research.
Who invested in Alpha Nuclide
4 investors across 2 rounds
See all investors in Alpha Nuclide
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Alpha Nuclide
Who invested in Alpha Nuclide?
Alpha Nuclide has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Alpha Nuclide raised?
Alpha Nuclide has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Alpha Nuclide last raise money?
Alpha Nuclide's most recent round on record is a Series A, in Feb 2026.
What does Alpha Nuclide do?
, trading as Alpha Nuclide, is a drug developer dedicated to nuclide drug research.
Where is Alpha Nuclide headquartered?
Alpha Nuclide is headquartered in Ningbo, China.
Which VCs invest in companies like Alpha Nuclide?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Alpha Nuclide's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Alpha Nuclide? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.